Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

November 30, 2006

Conditions
ADHD, ADD
Interventions
DRUG

Dexmethylphenidate HCl extended-release capsules

Trial Locations (25)

10029

Novartis Investigational Site, New York

10032

Novartis Investigational Site, New York

10305

Novartis Investigational Site, Staten Island

19149

Novartis Investigational Site, Philadelphia

27514

Novartis Investigational Site, Chapel Hill

27609

Novartis Investigational Site, Raleigh

30083

Novartis Investigational Site, Stone Mountain

32751

Novartis Investigational Site, Maitland

32806

Novartis Investigational Site, Orlando

38119

Novartis Investigational Site, Memphis

38305

Novartis Investigational Site, Jackson

43205

Novartis Investigational Site, Columbus

60048

Novartis Investigational Site, Libertyville

66206

Novartis Investigational Site, Prairie Village

66211

Novartis Investigational Site, Overland Park

72205

Novartis Investigational Site, Little Rock

77007

Novartis Investigational Site, Houston

80304

Novartis Investigational Site, Boulder

85210

Novartis Investigational Site, Mesa

89128

Novartis Investigational Site, Las Vegas

90095

Novartis Investigational Site, Los Angeles

97030

Novartis Investigational Site, Gresham

02138

Novartis Investigational Site, Cambridge

08855

Novartis Investigational Site, Piscataway

08755

Novartis Investigational Site, Toms River

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00301236 - Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter